You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
This included the following abstracts:
While there wasn’t much original new programming and research presented on the final day, that didn’t slow the RheumNow faculty from tweeting the noteworthy “Best of ACR” abstracts. Enjoy these below.
The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations.
Today was a big day for the Plenaries, Curbside Consult
The Merriam-Webster definitions of “plenary” include: 1. complete in every respect: absolute, unqualified and 2. fully attended or constituted by all entitled to be present.
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23.
THE GREAT DEBATE
ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?
There has been much discussion of late regarding the important topic of how best to manage the independent cardiovascular risk associated with rheumatoid arthritis and other rheumatic diseases.
Links:
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
